- SPACs
- IB Acquisition Corp.
IB Acquisition Corp.
Definitive agreement 2026-03-16- CIK 1998781
- IBAC
- IPO 2024-03-27
- $8.3M trust
- 87 filings
- IPO Size
- $115M
- raised at the IPO
- Trust
- $8.3M
- as of 2026-06-30
- Current Status
- Definitive Agreement
- from its latest filing
- IPO Year
- 2024
- year it listed
Filings, by quarter
87 filings over 13 quarters; violet bars carry a milestone
- 23 Q4: 4 filings
- 24 Q1: 20 filings
- 24 Q2: 8 filings
- 24 Q3: 2 filings
- 24 Q4: 3 filings
- 25 Q1: 2 filings
- 25 Q2: 1 filing
- 25 Q3: 6 filings
- 25 Q4: 13 filings
- 26 Q1: 14 filings
- 26 Q2: 3 filings
- 26 Q3: 10 filings
- 26 Q4: 1 filing
- S-1 filed 23 Q4
- IPO 24 Q1
- Definitive agreement 26 Q1
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
- Registration2023-11-17 Filed S1
- IPO2024-03-27 IPO, search begins
- Definitive Agreement2026-03-16 Agreement for merger
- CompletedNot yet completed
About
IB Acquisition Corp. is a blank-check company seeking a business combination with high-growth companies. Its stated interest areas include fintech, healthcare and life sciences, sports and entertainment, and consumer goods; it expects to target companies domiciled in North America, Europe, or Asia with enterprise value of at least $500 million.
Investment Focus
FinTech, Healthcare, Biopharmaceuticals, Sports, Entertainment, Consumer
Geographic Focus
North America, Europe, Asia
Key Information
As the filings state it
- IPO Date
- 2024-03-27
- Total Redemptions
- $115M
- PIPE
- $16.5M
- Jurisdiction of Incorporation
- Nevada
- SIC
- 6770
- Merger Target
- GNQ Insilico, Inc.
- SPAC Ticker
- IBAC
Stock Performance
IBACTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2024-05-01 | $9.96 | |
| Current Price | 2026-10-14 | $10.86 | +9% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The management team has experience in private investing, corporate finance, restructuring and executive management. Members include executives with backgrounds at IBM and other major companies, financial-services and biotech leaders, and a venture-capital investor.